- Home
- DGII vs ETNB Comparison
DGII vs ETNB Comparison
Compare DGII & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- ETNB
- Stock Information
- Founded
- DGII 1985
- ETNB 2018
- Country
- DGII United States
- ETNB United States
- Employees
- DGII N/A
- ETNB N/A
- Industry
- DGII Computer peripheral equipment
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- ETNB Health Care
- Exchange
- DGII Nasdaq
- ETNB Nasdaq
- Market Cap
- DGII 1.3B
- ETNB 1.5B
- IPO Year
- DGII N/A
- ETNB 2019
- Fundamental
- Price
- DGII $36.27
- ETNB $8.07
- Analyst Decision
- DGII Buy
- ETNB Strong Buy
- Analyst Count
- DGII 4
- ETNB 10
- Target Price
- DGII $38.75
- ETNB $27.22
- AVG Volume (30 Days)
- DGII 198.6K
- ETNB 1.3M
- Earning Date
- DGII 11-12-2025
- ETNB 11-06-2025
- Dividend Yield
- DGII N/A
- ETNB N/A
- EPS Growth
- DGII 147.46
- ETNB N/A
- EPS
- DGII 1.14
- ETNB N/A
- Revenue
- DGII $420,935,000.00
- ETNB N/A
- Revenue This Year
- DGII $2.46
- ETNB N/A
- Revenue Next Year
- DGII $7.77
- ETNB N/A
- P/E Ratio
- DGII $31.36
- ETNB N/A
- Revenue Growth
- DGII N/A
- ETNB N/A
- 52 Week Low
- DGII $22.39
- ETNB $4.16
- 52 Week High
- DGII $37.07
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- DGII 61.22
- ETNB 50.83
- Support Level
- DGII $35.01
- ETNB $8.33
- Resistance Level
- DGII $36.94
- ETNB $9.47
- Average True Range (ATR)
- DGII 1.00
- ETNB 0.38
- MACD
- DGII 0.18
- ETNB -0.51
- Stochastic Oscillator
- DGII 80.88
- ETNB 84.15
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).